SGIOY News and Press, Shionogi & Co. Ltd. ADR From 02/01/22

ViiV Healthcare, majority-owned by GlaxoSmithKline (NYSE:GSK), announced that the FDA approved an every-two-month dosing regimen of the company’s HIV therapy Cabenuva, a combination of cabotegravir and rilpivirine. Cabotegravir and rilpivirine were developed by ViiV and Janssen unit of...

The following slide deck was published by Shionogi & Co., Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Shionogi & Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation

Viiv Healthcare, which is majority-owned by GlaxoSmithKline (GSK +0.6%),  with Pfizer (PFE -1.2%) and Shionogi (OTCPK:SGIOY -0.6%) as shareholders, has submitted an application to the FDA seeking a new formulation of its HIV pill Triumeq (abacavir/ dolu...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Total return for Harding Loevner International Equity Fund net of fees was 5.43% vs. MSCI All Country World ex-US ...

ViiV Healthcare has initiated a rolling submission of a new drug application ((NDA)) with the FDA for investigational, long-acting, injectable cabotegravir for the prevention of HIV, also called pre-exposure prophylaxis, or PrEP. The complete submission will be based on results from two ...

Merck ([[MRK]] +1.2%) has partnered with Gilead Sciences ([[GILD]] +0.8%) to co-develop and co-commercialize long-acting treatments targeting people living with HIV.The combination will bring together two experimental therapies of companies: Gilead’s capsid inhibitor, lenacap...

ViiV Healthcare announces the European Marketing Authorization of Rukobia (fostemsavir) 600mg extended-release tablets, a HIV attachment inhibitor, for use in combination with other antiretroviral ((ARV)) therapies for treatment of adults with multidrug-resistant HIV-1 infection. Fostemsavir,...

The following slide deck was published by Shionogi & Co., Ltd. in conjunction with their 2021 Q3 earnings call. For further details see: Shionogi & Co., Ltd. 2021 Q3 - Results - Earnings Call Presentation

The FDA has approved Johnson & Johnson (JNJ) unit, Janssen Pharmaceuticals' Cabenuva (consisting of Janssen's rilpivirine and ViiV Healthcare's cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infecti...

ViiV Healthcare announces the authorization of Vocabria (cabotegravir injection and tablets) in combination with Johnson & Johnson (JNJ) unit, Janssen Pharmaceuticals' Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the European Union ((EU)), for the treat...